Quick Answer
PMV Pharmaceuticals, Inc. reported Cash and Equivalents of $37.98 million for fiscal year 2025.
PMV Pharmaceuticals, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $37.98M | -7.1% |
| 2024 | $40.88M | +8.4% |
| 2023 | $37.71M | -65.2% |
| 2022 | $108.30M | -37.2% |
| 2021 | $172.47M | -52.3% |
| 2020 | $361.42M | +393.2% |
| 2019 | $73.28M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $36.34M | -25.6% | -17.7% |
| June 30, 2025 | $44.13M | -9.1% | -14.1% |
| March 31, 2025 | $51.34M | +7.7% | +25.6% |
| December 31, 2024 | $40.88M | +8.4% | -16.3% |
| September 30, 2024 | $48.81M | -6.2% | +0.6% |
| June 30, 2024 | $48.53M | -28.9% | +1.8% |
| March 31, 2024 | $47.65M | -66.7% | +26.4% |
| December 31, 2023 | $37.71M | -65.2% | -27.6% |
- PMV Pharmaceuticals, Inc. showed a decrease of -7.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2025 period, PMV Pharmaceuticals, Inc.’s cash and equivalents has declined by 48.2% (from $73.28 million to $37.98 million).
- The most recent figure is from PMV Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 6, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: